Ibrutinib & zanubrutinib Q&A


We know that the recent NICE decisions about the drugs ibrutinib and zanubrutinib are a cause for worry for many in the WM community. Our CEO, Jane Nicholson, who has been working with NICE and the drug companies involved during the processes joins us for a Q&A session about what the decisions mean for you, [...]